💥 Gate Square Event: #PostToWinCC 💥
Post original content on Gate Square related to Canton Network (CC) or its ongoing campaigns for a chance to share 3,334 CC rewards!
📅 Event Period:
Nov 10, 2025, 10:00 – Nov 17, 2025, 16:00 (UTC)
📌 Related Campaigns:
Launchpool: https://www.gate.com/announcements/article/48098
CandyDrop: https://www.gate.com/announcements/article/48092
Earn: https://www.gate.com/announcements/article/48119
📌 How to Participate:
1️⃣ Post original content about Canton (CC) or its campaigns on Gate Square.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostTo
AstraZeneca's breast cancer drug Enhertu shows better efficacy in preventing recurrence compared to competitors and is expected to cure early-stage patients.
Jin10 reported on October 20 that AstraZeneca and Japan's Daiichi Sankyo's cancer drug Enhertu has shown better treatment outcomes for early breast cancer patients. In two key trials presented at the European Society for Medical Oncology meeting held in Berlin last weekend, Enhertu outperformed Roche's Kadcyla in preventing disease recurrence, and was more effective when used prior to surgery.